ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO828

Urinary Galectin-3 Binding Protein as a Predictive Marker for Lupus Nephritis Flare

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation


  • Parikh, Samir V., Ohio State University Wexner Medical Center, Columbus, Ohio, United States
  • Zhang, Xiaolan, Ohio State University Wexner Medical Center, Columbus, Ohio, United States
  • Bassi, Roberto, EMD Serono R&D Institute, Rockland, Massachusetts, United States
  • Varghese, Sneha, EMD Serono R&D Institute, Rockland, Massachusetts, United States
  • Mehta, Pramod P., MilliporeSigma, St Louis, Missouri, United States
  • Lie, Wen-Rong, MilliporeSigma, St Louis, Missouri, United States
  • Okitsu, Shinji L., EMD Serono Research and Development Institute, Billerica, Massachusetts, United States
  • Rovin, Brad H., Ohio State University Wexner Medical Center, Columbus, Ohio, United States

Identifying predictive markers of lupus nephritis (LN) flare has been elusive but is necessary to improve outcomes. Serum galectin-3 binding protein (G3BP) is correlated with interferon signature in active SLE. We aimed to define the specificity of urine G3BP (uG3BP) as marker of LN flare and determine its ability to predict flare and response to treatment.


uG3BP protein expression was measured from urine collected at the time of kidney biopsy and compared across multiple glomerular diseases including active LN (n=97), IgA nephropathy (n=27), diabetic nephropathy (n=10), primary membranous nephropathy (n=10), ANCA-associated vasculitis (n=4) and healthy controls (n=20). Additionally, active LN expression was compared to LN remission (n=52). uG3BP levels were normalized for urinary creatinine (Cr). To examine uG3BP expression longitudinally, urine from the Ohio SLE cohort study (OSS) of 27 LN patients (44 flares) was measured by ELISA at 5 different time points; -4, -2, flare, +2, and +4 months post flare. uG3BP expression was compared between each time point to understand if uG3BP is a sensitive marker to predict the development and resolution of inflammation in LN.


uG3BP expression was significantly increased in all tested kidney diseases, except ANCA compared to healthy controls (p<0.0001). The highest concentration of uG3BP was found in active LN (423.79±32.06 ng G3BP/mg Cr). uG3BP expression was significantly greater at LN flare compared to controls (423.79±32.06 vs 44.8 ng G3BP/mg cr, p<0.0001), IgA nephropathy (423.79±32.06 vs 138 ng G3BP/mg Cr, p<0.0001) and remisison LN (423.79±32.06 vs127.5 ng G3BP/mg Cr, p<0.0001). uG3BP expression increased incrementally from 4 months pre-flare to flare, peaked 2 months post-flare (p=0.02 compared to flare levels) and significantly decreased 4 months post-flare (p=0.01).


uG3BP, while not specific, is highly expressed at LN flare reflecting interferon activation. uG3BP expression may predict LN flare but due to limited samples size data are currently inconclusive. Further investigation is warranted. uG3BP expression may be a predictive marker of treatment response.


  • Commercial Support